Patrick J. Zenner Elected to Board of Directors of Par Pharmaceutical Companies, Inc.

Patrick J. Zenner Elected to Board of Directors of Par Pharmaceutical Companies, Inc.

WOODCLIFF LAKE, N.J., July 22 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE:PRX) today announced that Patrick J. Zenner has been elected to the company's board of directors. Mr. Zenner was also appointed to the Compensation and Management Development Committee and the Corporate Development Review Committee.
 

Mr. Zenner retired in January 2001 from Hoffmann-La Roche Inc., North America, where he served as President and Chief Executive Officer since 1993. Mr. Zenner held various executive positions during his 32-year career with Hoffmann-LaRoche. Currently, Mr. Zenner is Chairman of the Board of ArQule, Inc. and Exact Sciences Corporation and a director of West Pharmaceutical Services. He is also a member of the Board of Trustees of Creighton University and is Chairman of the Board of Trustees of Fairleigh Dickinson University.
 

Patrick G. LePore, Par's Chairman, Chief Executive Officer, and President, said, "I am very pleased to welcome an executive of Pat's caliber to our board. He has a detailed knowledge of the pharmaceutical industry and has extensive board experience. We look forward to working with him and benefiting from his substantial knowledge and leadership skills."
 

About Par Pharmaceutical Companies, Inc.
 

Par Pharmaceutical Companies, Inc. is a US-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press release and other company information, visit www.parpharm.com.
 

Source: Par Pharmaceutical Companies, Inc.

CONTACT: Allison Wey , Vice President, Investor Relations and Corporate
Affairs, Par Pharmaceutical Companies, Inc., +1-201-802-4000
 

Web Site: http://www.parpharm.com/

 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.